Urol. praxi. 2021;22(4):181-184 | DOI: 10.36290/uro.2021.037

Hyaluronic acid: prevention and treatment of urological toxicity in cancer therapy

MUDr. Jiří Klečka, Ph.D., MBA
Urologická klinika, 3. LF UK Královské Vinohrady, Praha
UroCentrum Plzeň

Hyaluronic acid is a substance naturally occurring in the human body. It is part of the glycosaminoglycan layer found on the surface of the bladder urothelium and in eye and joint fluids. This type of agent is administered directly into the bladder and expected to temporarily replace the glycosaminoglycan layer therein which may be damaged in patients with interstitial cystitis. The effect of hyaluronic acid is pluripotent, being used both in preventing the toxic effects of cancer treatment, particularly of radiotherapy, and in treating chronic lower urinary tract infections caused by bacteria and/or autoimmunity in the case of interstitial cystitis.

Keywords: hyaluronic acid, glycosaminoglycan layer, recurrent urinary tract infection, anticancer treatment toxicity.

Published: November 24, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Klečka J. Hyaluronic acid: prevention and treatment of urological toxicity in cancer therapy. Urol. praxi. 2021;22(4):181-184. doi: 10.36290/uro.2021.037.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Parsons CL, Greenspans C, Mulholland S. The primary antibacterial defense mechanism of the bladder. Invest Urol 1975; 13: 72-76. Go to PubMed...
    2. Morales A, Emerson L, Nickel JC, Lundie M. Intravesical hyaluronic acid in the treatment of refraktory interstitial cystitis. J Urol 1996; 156(1): 45-48. Go to original source... Go to PubMed...
    3. Rooney P, Srivastava A, Watson L, Quinlan LR, Pandit A. Hyaluronic acid decreases IL-6 and IL-8 secretion and permeability in an inflammatory model of interstitial cystitis. Acta Biomater 2015; 19: 66-75. doi: 10.1016/j.actbio.2015. 02. 030. Go to original source... Go to PubMed...
    4. Tay H, Parsons CL, Stein PC. Electrophysiologic monitoring of the effects of soluble virulence factors produced by Escherichia coli infection in urine. Urology 1996; 48(3): 389-392. doi: 10.1016/s0090-4295(96)00209-9. Go to original source... Go to PubMed...
    5. Hohlbrugger G. Urinary potassium and the overactive bladder. Br J Urol Int 1999; 83 (Suppl 2): 22-28. Go to original source... Go to PubMed...
    6. Hohlbrugger G & Riedl C. Non-bacterial cystitis. Curr Opin Urol 2000; 10: 371-380. Go to original source... Go to PubMed...
    7. Metts JF. Interstitial cystitis: urgency and frequency syndrome. Am Fam Physician 2001; 64: 1199-1206. Go to PubMed...
    8. Peeker R, Fall M. Treatment guidelines for classic and non-ulcer interstitial cystitis. Int Urogynecol J 2000; 11: 23-32. Go to original source... Go to PubMed...
    9. Hanno PM, Wein AJ. Medical treatment of interstitial cystitis (other than Rimso-50/Elmiron). Urology 1987; 29(Suppl. 4): 22-26. Go to original source... Go to PubMed...
    10. French LM, Bhambore N. Interstitial cystitis/painful bladder syndrome. Am Fam Physician 2011; 83: 1175-1181. Go to PubMed...
    11. Parsons CL, Lilly JD, Stein P. Epithelial dysfunction in nonbacterial cystitis (interstitial cystitis). J Urol 1991; 145: 732-735. Go to original source... Go to PubMed...
    12. Marshall K. Interstitial cystitis: understanding the syndrome. Altern Med Rev 2003; 8: 426-437.
    13. Ratliff TL, Klutke CG, McDougall EM. The etiology of interstitial cystitis. Urol Clin North Am 1994; 21: 21-30. Go to original source... Go to PubMed...
    14. Rosamilia A, Dwyer PL. Interstitial cystitis and the gynecologist. Obstet Gynecol Surv 1998; 53: 309-319. Go to original source... Go to PubMed...
    15. International Painful Bladder Foundation. Interstitial cystitis and the painful bladder. Available at: http://www.painful-bladder.org/pdf/IPBF%20 Publ%2004%20UK.pdf [Accessed October 2012].
    16. Nickel JC. Interstitial cystitis. Etiology, diagnosis, and treatment. Can Fam Physician 2000; 46: 2430-2434, 2437-2440.
    17. Ho N, Koziol JA, Parsons CL. Epidemiology of interstitial cystitis. Sant GR (ed.) Interstitial Cystitis. Philadelphia: Lippincott-Raven 1997: 9-16.
    18. Moutzouris DA, Falagas ME. Interstitial cystitis: an unsolved enigma. Clin J Am Soc Nephrol 2009; 4: 1844-1857. Go to original source... Go to PubMed...
    19. Rovner E. Interstitial cystitis treatment and management. Available at: http://emedicine. medscape.com/article/2055505-treatment#aw2a¬ab6b5b8 [Accessed October 2012].
    20. Lazarou G. Interstitial cystitis. Available at: http://www.emedicinehealth. com/interstitial_ cystitis/article_em.htm [Accessed October 2012].
    21. Kallestrup EB, Jorgensen SS, Nordling J, et al. Treatment of interstitial cystitis with Cystistat®: a hyaluronic acid product. Scand J Urol Nephrol 2005; 39: 143-147. Go to original source... Go to PubMed...
    22. International Painful Bladder Foundation. International painful bladder syndrome, Bladder pain syndrome, Hypersensitive bladder syndrome, Chronic pelvic pain-Diagnosis & treatment. Available at: http://www. painful-bladder.org/treatment.html [Accessed October 2012].
    23. Parsons CL. The therapeutic role of sulfated polysaccharides in the urinary bladder. Urol Clin North Am 1994; 21: 93-100. Go to original source... Go to PubMed...
    24. Parsons CL, Stein PC, Bidair M, et al. Abnormal sensitivity to intravesical potassium in interstitial cystitis and radiation cystitis. Neurourol Urodyn 1994; 13: 515-520. Go to original source... Go to PubMed...
    25. Hurst RE. Structure, function, and pathology of proteoglycans and glycosaminoglycans in the urinary tract. World J Urol 1994; 12: 3-10. Go to original source... Go to PubMed...
    26. Morales A, Emerson L, Nickel JC, et al. Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis. J Urol 1996; 156: 45-48. Go to original source... Go to PubMed...
    27. Hurst RE, Roy JB, Parsons CL. The role of glycosaminoglycans in normal bladder physiology and the pathophysiology of interstitial cystitis. Sant GR (ed.) Interstitial Cystitis. Philadelphia: Lippincott-Raven 1997: 9-16.
    28. Porru D, Campus G, Tudino D, et al. Results of treatment of refractory interstitial cystitis with intravesical hyaluronic acid. Urol Int 1997; 59: 26-29. Go to original source... Go to PubMed...
    29. McCarty MF. Enhanced synovial production of hyaluronic acid may explain rapid clinical response to high-dose glucosamine in osteoarthritis. Med Hypotheses 1998; 50: 507-51. Go to original source... Go to PubMed...
    30. Samper Ots PM, López Carrizosa C, Rodríguez A, de Dios Sáez J, Delgado JM, de Miguel MM, Vidal M. Vesical instillations of hyaluronic acid to reduce the acute vesical toxicity caused by high-dose brachytherapy do not affect the survival: a five year follow-up study. Clin Transl Oncol 2009; 11: 828-834 Go to original source... Go to PubMed...
    31. Mañas A, Glaría L, Peña C, et al. Prevention of urinary tract infections in palliative radiation for vertebral metastasis and spinal compression: a pilot study in 71 patients. Int J Radiat Oncol Biol Phys 2006; 64: 935-940. Go to original source... Go to PubMed...
    32. Sommariva ML, Sandri SD, Ceriani V. Efficacy of sodium hyaluronate in the management of chemical and radiation cystitis. Minerva Urol Nefrol 2010; 62: 145-150. Go to PubMed...
    33. Horňák J, Veselý Š, Havlová K, Babjuk M. Prevence recidivujících cystitid pomocí roztoku hyaluronátu sodného Flaveran. Ces Urol 2020; 24(3): 207-213.
    34. Ying-Lun Ou, MDa, Chin-Yu Liu. Complete reversal of the clinical symptoms and image morphology of ketamine cystitis after intravesical hyaluronic acid instillation - a case report. Medicine 2018; 97: 28. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.